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Abstract
Background—We investigated the effect of influenza vaccination on disease severity in adults 
hospitalized with laboratory-confirmed influenza during 2013–14, a season in which vaccine 
viruses were antigenically similar to those circulating.
Methods—We analyzed data from the 2013–14 influenza season and used propensity score 
matching to account for the probability of vaccination within age strata (18–49, 50–64, and ≥65 
years). Death, intensive care unit (ICU) admission, and hospital and ICU lengths of stay (LOS) 
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were outcome measures for severity. Multivariable logistic regression and competing risk models 
were used to compare disease severity between vaccinated and unvaccinated patients, adjusting for 
timing of antiviral treatment and time from illness onset to hospitalization.
Results—Influenza vaccination was associated with a reduction in the odds of in-hospital death 
among patients aged 18–49 years (adjusted odds ratios [aOR] = 0.21; 95% confidence interval 
[CI], 0.05 to 0.97), 50–64 years (aOR = 0.48; 95% CI, 0.24 to 0.97), and ≥65 years (aOR = 0.39; 
95% CI, 0.17 to 0.66). Vaccination also reduced ICU admission among patients aged 18–49 years 
(aOR = 0.63; 95% CI, 0.42 to 0.93) and ≥65 years (aOR = 0.63; 95% CI, 0.48 to 0.81), and 
shortened ICU LOS among those 50–64 years (adjusted relative hazards [aRH] = 1.36; 95% CI, 
1.06 to 1.74) and ≥65 years (aRH = 1.34; 95% CI, 1.06 to 1.73), and hospital LOS among 50–64 
years (aRH = 1.13; 95% CI, 1.02 to 1.26) and ≥65 years (aRH = 1.24; 95% CI, 1.13 to 1.37).
Conclusions—Influenza vaccination during 2013–14 influenza season attenuated adverse 
outcome among adults that were hospitalized with laboratory-confirmed influenza.
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Influenza vaccination is the best strategy for preventing influenza [1]. Nonetheless, influenza 
vaccination coverage in the United States is suboptimal, especially among adults 18 to 49 
years of age, with vaccination levels as low as ~33% [2]. Reasons for low coverage may 
include underappreciation of disease severity and skepticism among the public about how 
well the vaccine works [3].
Although prevention of influenza virus infection is the desirable outcome after influenza 
vaccination, people may still become infected with influenza despite being vaccinated [4]. 
However, some studies have suggested that influenza vaccination could modify the severity 
of illness among vaccinated patients who subsequently develop influenza virus infection [5–
8]. Evidence for vaccine modification of influenza-associated disease severity could be an 
important argument toward improving influenza vaccination coverage in various groups of 
the population.
Influenza vaccine effectiveness (VE) varies from season to season, depending on host 
characteristics (such as age and presence of comorbidities) and how well circulating 
influenza viruses match the viruses contained in the vaccine [9–12]. During the 2013–14 
influenza season, influenza A(H1N1) pdm09 virus predominated, the first time in the United 
States since this virus emerged in 2009 [13]. During that season, influenza viruses that 
circulated were antigenically similar to viruses included in the vaccine, and the influenza VE 
estimate against medically attended acute respiratory illness for ages ≥6 months was 52% 
(95% confidence interval [CI] 44, 59) [9, 14], which allowed us to investigate the impact of 
influenza vaccination on disease severity. Therefore, we analyzed data from adults 
hospitalized with laboratory-confirmed influenza during the 2013–14 influenza season in the 
United States, to assess whether influenza vaccination provided protection against severe 
influenza disease among persons who become infected with influenza despite vaccination.
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METHODS
Study Population and Design
We analyzed population-based data from the US Influenza Hospitalization Surveillance 
Network (FluSurv-NET) that includes over 240 reporting hospitals, with a catchment area 
representing approximately 9% of the US population. Adult (age ≥18 years) residents of the 
surveillance area were considered cases if they were admitted to one of the participating 
hospitals from October 1, 2013, through April 30, 2014, and had a laboratory-confirmed 
diagnosis of influenza no more than 14 days before admission. Influenza testing and the type 
of influenza testing used (i.e., reverse transcription–polymerase chain reaction, viral culture, 
fluorescent antibody staining, or rapid antigen test) was determined by the provider. Medical 
chart review using a standardized form captured information on demographic characteristics 
and clinical outcomes during hospitalization [15].
Vaccination status was ascertained from medical charts and vaccine registries by contacting 
the patient’s primary care provider or by interviewing the patient or proxies directly. A 
complete or partial vaccination date had to be provided in order for the patient to be 
considered vaccinated. If these criteria were not met, at least one vaccination source had to 
indicate that the patient did not receive seasonal influenza vaccination [on or after July 1, 
2013] to be considered unvaccinated for that season; otherwise vaccination status of the 
patient was considered unknown.
We excluded cases with unknown vaccination status and cases who had fewer than 14 days 
between vaccination and hospitalization (time required to develop vaccine-induced 
protection). We also excluded those living in long-term care facilities because of substantial 
differences in baseline characteristics (e.g., vaccination coverage, frailty, and 
immunosenescence) as compared to adults living in the community [16]. Over 80% of the 
captured FluSurv-NET patients received antiviral medication (oseltamivir). We did not have 
information on why physicians treated some patients and not others; moreover, there were 
significant differences between patients who received antivirals and patients who did not 
(data not shown). Therefore, we decided to exclude patients who did not receive antivirals, 
those with an unclear history of antiviral treatment, and those who started antiviral treatment 
≥4 days before hospitalization (because we could not ascertain whether treatment was 
completed). The group of patients who were not treated with antiviral was small to be 
analyzed separately. Also, we excluded pregnant women and those without body mass index 
(BMI) data.
Severity Outcomes
We evaluated intensive care unit (ICU) admission, in-hospital death (including hospice 
transfer), diagnosis of pneumonia, and ICU and hospital length of stay (LOS) as measures of 
disease severity (study outcomes). Pneumonia was defined by presence of 
bronchopneumonia/pneumonia, air space density/opacity, pleural effusion/empyema, 
consolidation and/or lobar (not interstitial) infiltrate on chest radiography within the first 3 
days of hospital admission, and a discharge diagnosis of pneumonia. For the analysis of the 
impact of influenza vaccination on pneumonia, our denominator included only those who 
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had chest radiography taken within the first 3 days of hospital admission. All analyses were 
performed by age stratum (18–49, 50–64, and ≥65 years) because vaccine response and 
coverage varies by age [4, 17–19].
Statistical Analysis
We described epidemiologic and clinical characteristics of patient-population by vaccination 
status, using Pearson X2 test, Fisher exact test, or Wilcoxon-Mann-Whitney test.
For each age group mentioned above, we performed propensity score matching (PSM) to 
balance the differences between vaccinated and unvaccinated groups based on their 
probability of being vaccinated [20], given differences in demographic characteristics (sex, 
age, and race/ethnicity, and state of residence), BMI, chronic underlying conditions (asthma, 
chronic lung disease, cardiovascular disease, chronic metabolic disease, neurologic disease, 
immunosuppression, blood disorder, renal disease, and liver disease), and lifestyle risk 
factors (alcohol abuse and smoking). For PSM, we used the nearest neighbor matching 
approach, which requires a 1:2 vaccinated-to-unvaccinated ratio for best model fit [21, 22]. 
For adults ≥65 years, because we had a similar number of vaccinated and unvaccinated 
patients, we randomly sampled approximately 1/2 of vaccinated patients to meet the 1:2 
matching requirement. We repeated the random sample selection a thousand times to obtain 
an averaged point estimate for each outcome and lower and upper 95% CI [23]. After PSM, 
no significant differences remained for each of these variables by vaccination status.
Finally, for each age group, we evaluated the association of influenza vaccination with ICU 
admission, death, and pneumonia using multivariable logistic regression (MLR) models, 
adjusting odds ratios (aOR) for timing of antiviral treatment (calculated from day of 
symptom onset and categorized as ≤2 days, 3–5 days, and >5 days), and day to hospital 
admission (calculated from symptom onset and categorized as ≤2 days and >2 days). 
Similarly, we used competing risk (CR) models to evaluate the association of influenza 
vaccination and ICU and hospital LOS (in days), adjusting relative hazards (aRH) for timing 
of antiviral treatment and time to hospital admission, and accounted for in-hospital death as 
a CR. All analyses were performed using R software (version 3.2.2).
Ethics
FluSurv-NET was considered nonresearch for public health purposes by the institutional 
review board (IRB) at the Centers for Disease Control and Prevention (CDC). Participating 
sites submitted the FluSurv-NET protocol to its state and local IRBs for review, if required.
RESULTS
Baseline Characteristics (Before Propensity Score Matching)
Of the 8354 hospitalized adult cases that were identified in the 2013–14 season, 3444 (41%) 
were excluded, leaving 4910 cases for analysis (Figure 1). There were 1551 cases aged 18–
49 years (31.6%), 1771 were 50–64 years (36.1%), and 1588 were ≥65 years (32.3%); age 
group-specific influenza vaccination coverage was 19%, 33%, and 54%, respectively. 
Vaccinated cases were more likely to have chronic medical conditions than unvaccinated 
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cases, except among those aged ≥65 years, in whom fewer differences in the prevalence of 
medical conditions were observed. Influenza vaccination was inversely associated with 
smoking among adults ≥50 and with alcohol abuse in those 50–64 years of age. In addition, 
among adults aged 18–64 years, influenza vaccination was associated with earlier antiviral 
treatment and with receiving hospital care within 2 days of symptom onset (P < .02; Table 
1).
Within each age group, the proportion of in-hospital deaths among the unvaccinated was 
higher than among the vaccinated (P < .04). Among those aged 18–49 and ≥65 years, a 
higher proportion of unvaccinated cases were admitted to the ICU as compared to the 
vaccinated group (P ≤ .01). For those aged 18–49 years, diagnosis of pneumonia was more 
likely among the unvaccinated (P = .01). For those 50–64 years, the median of ICU LOS 
was higher among the unvaccinated as compared to the vaccinated (P = .03).
Propensity Score Matching and Evaluation of Influenza Vaccination and Severe Disease 
Outcomes
After performing PSM on the probability of being vaccinated, we obtained matched samples 
of 600, 1186, and 732 cases among 18–49, 50–64, and ≥65 year age groups, respectively. 
We found no differences in proportions for any of the variables used for PSM by vaccination 
status (data not shown). For those aged 18–49 years, we found a protective effect of 
influenza vaccine against ICU admission (aOR = 0.63; 95% CI, 0.42 to 0.93) and in-hospital 
death (aOR = 0.21; 95% CI, 0.05 to 0.97). For those aged 50–64 years, we found a 
protective effect of the vaccine against in-hospital death (aOR = 0.48; 95% CI, 0.24 to 0.97), 
shorter ICU LOS (aHR for ICU discharge = 1.36; 95% CI, 1.06 to 1.74), and shorter hospital 
LOS (aHR for discharge = 1.13; 95% CI, 1.02 to 1.26). For those aged ≥65 years, we found 
a protective effect of the vaccine against ICU admission (aOR = 0.63; 95% CI, 0.48 to 0.81), 
in-hospital death (aOR = 0.39; 95% CI, 0.17 to 0.66), shorter ICU LOS (aRH = 1.34; 95% 
CI, 1.06 to 1.73), and shorter hospital LOS (aRH = 1.24; 95% CI, 1.13 to 1.37). We did not 
observe statistical differences for the association between influenza vaccination and 
pneumonia (Table 2). Figure 2 shows 95% CIs for the risk parameters evaluating the effect 
of influenza vaccination on influenza disease severity by 1000 random sample simulations 
for age group ≥65, after PSM and after adjusting for timing of antiviral treatment and time to 
hospital admission, and accounting for death in the survival models. In the graphs, the red 
lines represent 95% CI with a statistically significant value; the black lines represent 95% CI 
that did not achieve statistical significance. The 4 graphs show a trend of 95% CI toward 
rejecting the null hypothesis, which is consistent with results in Table 2. Figure 3 shows the 
cumulative incidence function for time to ICU discharge and hospital discharge for the 3 age 
groups, respectively. Overall, the probability of earlier discharge from the ICU or hospital, 
after accounting for in-hospital death, was higher for those vaccinated versus those 
unvaccinated at different points in time; this is also consistent with results in Table 2.
DISCUSSION
We showed a significant protective effect of 2013–14 seasonal influenza vaccination against 
disease severity outcomes among hospitalized adults with laboratory-confirmed influenza. 
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Overall, vaccinated adults had a 52–79% reduction in inhospital death and a 37% reduction 
in ICU admission (among those aged 18–49 and ≥65 years) compared to those unvaccinated. 
In addition, the probability of being discharged earlier from the ICU and from the hospital 
was 34–36% and 13–24% higher among vaccinated cases aged ≥50 years compared to 
unvaccinated cases. Our data suggest that although influenza vaccination may have failed to 
prevent influenza virus infection among some of those vaccinated for the 2013–14 season, it 
may have still protected those same people against more severe influenza-associated 
outcomes. Our findings underscore the importance of annual influenza vaccination for 
adults, particularly among those aged 18–49 years (historically the group with the lowest 
influenza vaccination coverage in the US) [2], and among those ≥65 years (accounting for 
71–85% of estimated annual influenza-associated deaths in the US) [24].
We had previously assessed the effect of influenza vaccination on disease severity among 
adults aged 50 years and older during the 2012–13 season using a similar analytical 
approach [5]. In that study, we did not find a substantial effect of vaccination on clinical 
outcomes (we only found a modest effect of vaccination on ICU LOS in the 50–64 year 
olds). Influenza season 2012–13 was primarily an H3N2 season with nonsignificant VE 
reported for older age groups [10, 25]. Influenza VE against medically attended cases due to 
influenza A in outpatients ≥65 years was 11% [95% CI –41 to 43] for the 2012–13 season, 
whereas the VE for the same age group during 2013–14 season was 51% (95% CI 12, 73) 
[10, 14]. Thus, the benefit of influenza vaccination on attenuating influenza-associated 
disease severity may be influenced by robustness of VE, especially among older adults.
Our analysis was limited to patients hospitalized with laboratory-confirmed influenza and 
those treated with antivirals; we do not know if our findings could be generalizable to non-
hospitalized populations or whether the effects we found could be even more robust in a 
population without access to antiviral treatment. Evidence to support the benefit of antiviral 
treatment in reducing influenza disease severity suggests that best results are seen if 
treatment initiated early (first 4 days after illness onset) [26–28] for which we account in our 
adjustment analysis. One of the explanations for not seeing a significant association between 
influenza vaccination and shorter ICU and hospital LOS among those aged 18–49 years may 
be the small sample size. Despite representing about one third of hospitalizations during the 
2013–14 season, a smaller percentage of cases within this age group were vaccinated. 
Interestingly, in this age group, we observed that influenza vaccination was associated with a 
lower prevalence of pneumonia compared to the unvaccinated group, which has been 
described elsewhere [29, 30]. However, when adjusted for all other characteristics, this 
association was no longer significant. Sample size could again explain that as the number of 
patients to assess pneumonia as an outcome was reduced to those with chest x-rays done 
within the first 3 days of admission.
Similar to our findings, one large multicenter case-control study in Spain [6] found a 
reduction of over 50% in the risk of severe influenza-related outcomes among those ≥65 
years old who were vaccinated against influenza. In addition, 2 smaller studies assessed 
2013–14 influenza vaccination in adults and its effects on disease severity. One of them [31] 
reported no effect of influenza vaccination on in-hospital mortality or respiratory failure 
among older adults hospitalized with influenza. In contrast, the other study reported lower 
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influenza vaccination rates among those who presented with more severe respiratory illness, 
including need for ICU admission and positive pressure ventilation [32]. These studies, 
unlike ours, were neither powered to control for confounders nor assessed the propensity for 
vaccination in their study population. Our findings suggest that, in addition to a VE against 
medically attended laboratory-confirmed influenza of about 50% in season 2013–14, 
influenza vaccination seemed to attenuate influenza-associated severe outcomes, including 
reduction in ICU admission and death.
Additional findings that support the benefit of influenza vaccination in attenuating influenza 
disease severity come from VE studies. Deiss et al [33], based on symptoms at disease 
presentation, described a milder disease among vaccinated individuals infected with H3N2 
viruses compared to unvaccinated individuals during the 2009–2014 seasons. Others have 
estimated VE for mild and severe cases separately, finding higher protection against severe 
cases that would suggest that influenza vaccine could attenuate illness [34, 35]. This implies 
that our study outcomes may not represent the full spectrum of the effect of influenza 
vaccination on disease attenuation. Therefore, studies assessing the benefit of annual 
influenza vaccination in terms of cases, hospitalizations, and/or deaths averted without 
including the potential for disease severity modification may be underestimating the total 
benefits of influenza vaccination [1, 12].
Observational studies of this kind demand robust methods to ensure that biases in the data 
are limited (e.g., vaccine is more commonly administered to patients with comorbidities and 
older adults). To minimize the impact of confounding by indication and healthy vaccinee 
bias, we used PSM to balance the comparison groups accounting for the probability of 
vaccination and used CR models to account for death during hospitalization that could affect 
our ability to assess LOS as a reliable measure of severity [36–38]. Nonetheless, our study 
has limitations. There might be unmeasured or incompletely measured confounders that we 
could not account for in PSM. We were reassured by the fact that we were able to include an 
extensive list of variables reported to be associated with vaccination in our PSM, achieving 
well-balanced comparison groups [26], and adjusting for other variables associated with the 
outcomes of interest in the final models. Nonetheless, the benefit of vaccination may have 
been underestimated because we only included in-hospital deaths. Future studies could 
evaluate the impact of influenza vaccination accounting for deaths occurring after hospital 
discharge [37]. We excluded 8% of participants due to unknown vaccination status that 
could inadvertently introduce bias; however, the number was not large, and when we 
compared the excluded group’s characteristics related to vaccination, severity, and time from 
disease onset to hospitalization, we did not find any substantial differences (Supplementary 
Table A1). We performed our analyses among hospitalized patients treated with antivirals, 
excluding untreated patients (less than 20% of FluSurv-NET patients) [16], and this could 
also have underestimated the effect of vaccination on influenza-associated severe outcomes 
as antiviral treatment can attenuate disease severity [39].
In conclusion, our study demonstrated that despite vaccinated individuals became infected 
with influenza viruses, vaccination can reduce disease severity. Our study focused on adults 
hospitalized with laboratory-confirmed influenza in 2013–14, a year in which the vaccine 
virus components matched the circulating viruses. This additional benefit of influenza 
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vaccination on disease severity may be observed in future seasons when vaccine is shown to 
provide significant protection, especially among people aged ≥65 years.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Figure 1. 
Exclusion criteria and data cleaning algorithm.
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Figure 2. 
Confidence intervals [95% CI] of severe disease outcomes obtained by random sample 
simulations (N = 1000) for age group 65 years and older.
Relative Hazard (RH) represents ICU or hospital discharge accounting for death; For age 
group 65+ years: aOR for ICU admission = 0.63 (95% CI: 0.48, 0.81), aOR for death = 0.39 
(95% CI: 0.17, 0.66), aRH for ICU Discharge = 1.34 (95% CI: 1.06, 1.73), aRH for Hospital 
Discharge = 1.24 (95% CI: 1.13, 1.37). Abbreviations: aOR, adjusted odds ratio; aRH, 
adjusted relative hazard; CI, confidence interval; ICU, intensive care unit.
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Figure 3. 
Cumulative incidence function for shorter ICU length of stay and length of hospital stay for 
age groups 18 to 49 years, 50 to 64 years, and 65 years and older by vaccination status 
accounting for death as a competing risk.
Relative Hazard (RH) represents ICU or hospital discharge accounting for death; For age 
group 18 to 49 years: RH for ICU Discharge = 1.40 (95% CI: 0.97, 2.02), RH for hospital 
discharge = 1.11 (95% CI: 0.95, 1.29). For age group 50 to 64 years: RH for ICU discharge 
= 1.36 (95% CI: 1.06, 1.74), RH for hospital discharge = 1.13 (95% CI: 1.02, 1.26). For age 
group 65+ years: RH for ICU discharge = 1.34 (95% CI: 1.06, 1.73), RH for hospital 
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discharge = 1.24 (95% CI: 1.13, 1.37). Abbreviations: CI, confidence interval; CIF, 
cumulative incidence function; ICU, intensive care unit; RH, relative hazard.
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as
e,
 im
m
un
os
up
pr
es
sio
n,
 b
lo
od
 d
iso
rd
er
,
 
re
n
al
 d
ise
as
e,
 
liv
er
 d
ise
as
e,
 a
nd
 h
av
in
g 
at
 le
as
t o
ne
 o
f t
he
se
 c
on
di
tio
ns
), a
nd
 al
co
ho
l a
bu
se
 a
n
d 
sm
ok
in
g.
b T
im
in
g 
fo
r a
nt
iv
ira
l t
re
at
m
en
t w
as
 c
al
cu
la
te
d 
fro
m
 sy
m
pt
om
 o
ns
et
 a
nd
 c
at
eg
or
iz
ed
 a
s ≤
2 
da
ys
, 3
–5
 d
ay
s, 
an
d 
>5
 d
ay
s o
r n
o 
tre
at
m
en
t; 
tim
e s
ee
ki
ng
 h
os
pi
ta
l c
ar
e (
≤2
 vs
 >2
 da
ys
).
c B
as
ed
 o
n 
10
00
 si
m
ul
at
io
ns
; p
oi
nt
 e
sti
m
at
e 
an
d 
lo
w
er
 a
n
d 
up
pe
r c
on
fid
en
ce
 in
te
rv
al
 re
pr
es
en
t 5
0t
h,
 2
.5
th
 an
d 
97
.5
th
 p
er
ce
nt
ile
s o
f p
oi
nt
 es
tim
at
es
 (n
 = 
10
00
), r
esp
ec
tiv
el
y.
d P
ne
um
on
ia
 a
na
ly
sis
 w
as
 p
er
fo
rm
ed
 a
m
on
g 
th
os
e 
w
ho
 h
ad
 c
he
st 
x-
ra
ys
 w
ith
in
 3
 d
ay
s o
f a
dm
iss
io
n.
e R
H
 re
pr
es
en
ts 
IC
U
 o
r h
os
pi
ta
l d
isc
ha
rg
e 
ac
co
un
tin
g 
fo
r d
ea
th
.
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